Bobby Liaw, MD, presents the case of a 73-year-old man with biochemical recurrence of prostate cancer and metastatic castration-sensitive high-volume disease.
A 73-Year-Old Man with Biochemical Recurrence of Prostate Cancer and Metastatic Castration-sensitive Disease
An oncologist details the first-line therapy options for metastatic castration-sensitive prostate cancer.
Dr. Bobby Liaw compares the available first-line therapy options for metastatic castration-sensitive prostate cancer and explains how to decide on a therapy.
A prostate cancer expert reviews the treatment approach in the presented case of biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease.
Bobby Liaw, MD, explains the potential treatment strategy for a prostate cancer case with low-volume metastatic disease.
A key opinion leader reviews how findings from the TITAN study affect treatment of metastatic castration-sensitive prostate cancer.
Dr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
